Akero Therapeutics

Thank you to every team member, collaborator, partner, researcher, clinician, patient and advocate who contributed to a great 2024 for #TeamAkero! We’re proud of all that’s been accomplished this year, including a successful 96-week readout of the Phase 2b HARMONY study, securing additional financing for patient enrollment in the Phase 3 SYNCHRONY program, and preparing our first marketing authorization application. As we approach 2025, we look forward to the upcoming readout of 96-week results from our Phase 2b SYMMETRY study and continued advancement of #EFX through Phase 3.

#TeamAkero will be at the J.P. Morgan 43rd Annual Healthcare Conference next month. If you’d like to learn more about Akero and our work developing therapeutics with the potential to transform the MASH treatment landscape, please reach out! We look forward to connecting with industry leaders, sharing insights, and exploring the latest innovations in #biotech.

Our Director of Translational Biology and Pharmacology, Erik Tillman, PhD, is presenting today at the Keystone Symposia on Molecular & Cellular Biology Fibrosis: Inflammation, Drivers, and Therapeutic Resolution. He will be sharing insights on progressive fibrosis improvement with #EFX over 96 weeks, based on concordance of imaging and circulating biomarkers with conventional and digital histopathology. View the poster on our website here: https://lnkd.in/etyDUvFn #KSFibrosis25

🦃 Happy Thanksgiving from #TeamAkero! #Thanksgiving

Join us next week as Akero participates in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference. Tune in to the live webcast of the session December 3rd at 9:10 AM ET through the investor relations section of our website. Learn more: https://lnkd.in/evjSMtuR #HealthCONx2024 #EvercoreISI

Greetings from San Diego! #TeamAkero had the pleasure of attending this year’s American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2024 to connect with leading experts, share our latest data and insights for #EFX, and engage in inspiring discussions about the future of MASH treatment. We're excited to continue advancing EFX through Phase 3 and look forward to seeing you all at future events! #TLM24 #Biotech #Innovation

Are you at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2024 this weekend? Join us on Sun, 11/17 at 2:00 PM PT for our oral presentation on #EFX week 96 data from our HARMONY study and visit our posters on Mon, 11/18 for insights on the latest trial data and AI-based digital pathology. Learn more: https://lnkd.in/ey-j-uED #TLM24

Today Akero reported Q3 2024 financial results and provided business updates. Read more at: https://lnkd.in/eXyXSfzM

A recent Endpoints News article written by Max Bayer discusses the opportunities for #MASH therapies to co-exist with GLP-1s, potentially offering enhanced benefits for patients struggling with the complex metabolic disorder. In the story, Max Bayer discusses how our lead drug #EFX can work synergistically with GLP-1s based on data from our Phase 2 Cohort D study evaluating patients with #MASH and type 2 diabetes: https://lnkd.in/gZVXhW6E Learn more about Akero: https://akerotx.com/

October is #NationalLiverAwarenessMonth! We recognize the vital role that our liver plays in our overall health and encourage everyone to learn more about metabolic diseases and their risk factors. #MASH is a severe form of #MASLD affecting an estimated 22 million American adults which can progress to cirrhosis, liver failure, cancer, and death. Take the American Liver Foundation’s liver health quiz today to check your risk for fatty liver diseases and know what questions to ask your doctor at your next check up: https://lnkd.in/gNWqRc3F